Skinny Labels Under the Microscope: What Hikma v. Amarin Means for Drug Developers
In today's evolving regulatory and legal landscape, few issues are as consequential for generic drug development as the use of so-called "skinny labels." The recent decision by the U.S. Supreme Court to hear Hikma Pharmaceuticals USA Inc. v. Amarin Pharma, Inc. has renewed scrutiny of this...




















